Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11524920 | 0.94 | IDO1 (0.43) | IDO1L3MBTL1MAPK1CACNA2D1CNR2 | |
| SCHEMBL11527742 | 0.92 | ADH1B (0.44) | IDO1L3MBTL1MAPK1CACNA2D1CNR2 | |
| SCHEMBL11526271 | 0.92 | ADH1B (0.44) | IDO1L3MBTL1MAPK1CACNA2D1CNR2 | |
| SCHEMBL10597073 | 0.92 | ADH1B (0.44) | IDO1L3MBTL1MAPK1CACNA2D1CNR2 | |
| SCHEMBL11342721 | 0.88 | KCNH3 (0.45) | IDO1POLBL3MBTL1MAPK1CACNA2D1 | |
| SCHEMBL23770556 | 0.87 | IDO1 (0.42) | IDO1POLBL3MBTL1MAPK1CACNA2D1 | |
| SCHEMBL4229486 | 0.87 | IDO1 (0.42) | IDO1POLBL3MBTL1RPS6KB1CNR2 | |
| SCHEMBL21799625 | 0.87 | IDO1 (0.42) | IDO1POLBL3MBTL1MAPK1CACNA2D1 | |
| SCHEMBL17467884 | 0.87 | POLB (0.46) | IDO1POLBL3MBTL1MAPK1RPS6KB1 | |
| SCHEMBL11277416 | 0.87 | SMN1; SMN2 (0.47) | POLBL3MBTL1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245123-B1 | METHODS FOR PRODUCING ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS | CHEMTURA CORP (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8563489-B2 | Alkylated 1,3-benzenediamine compounds and methods for producing same | CHEMTURA CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2245123-A2 | ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | Chemtura Corporation (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009076091-A2 | ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | CHEMTURA CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156449-A1 | ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | LANXESS SOLUTIONS US INC. | 2009-06-18 | — | — | US | disclosed |
| US-4337103-A | FUNCTIONALLY TERMINATED RUBBER | HERCULES INCORPORATED (US) | 1982-06-29 | — | — | US | disclosed |
| US-4140718-A | Preparation of N,N'-dialkylphenylenediamines | UOP INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-3982975-A | UNCURED CARBOXYLATED RUBBER, EPOXIDE CURING AGENT, PHENYLENEDIAMINE ANTIOXIDANT | HERCULES INCORPORATED (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156449-A1 | ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | BBOX1, ABHD5, BRD1 | IDO1 262/4885POLB 393/4885L3MBTL1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.